Using Continuous Glucose Monitors With Remote Viewing in Intensive Care
Looks at how safely a glucose sensor works for adults with diabetes in intensive care.
Key facts
- Who runs it
- Imperial College Healthcare NHS Trust
- Where
- London, United KingdomSee the site
- Trial code
- Registry title
- Implementation of Networked Continuous Glucose Monitoring With Telemetry Within the Intensive Care Unit (ICU-TeleCGM)
- Status
- Not yet recruiting
- People taking part
- 70 people, planned
- Started
- Aug 2026
- Expected to end
- Jun 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Dexcom G7
- ViewsEMR telemetry
- Record updated
- 17 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in intensive care (ICU) who have high blood sugar and need insulin. They wear a continuous glucose monitor, the Dexcom G7.
- Age
- Over 18 years (18 and older)
- Sex
- All sexes can join.
- Disease stage
- High blood sugar that needs insulin treatment (injection or into a vein) during the stay in intensive care. Admitted to intensive care within the last 48 hours.
Main reasons for not taking part
- Known significant allergy to tape or adhesives
- Death expected soon, or expected stay shorter than 24 hours
- Pregnant women
- ECMO expected soon (a machine that takes over heart and lung work)
- Needs therapeutic cooling after a cardiac arrest
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age >18years inclusive
- Hyperglycaemia requiring insulin therapy (subcutaneous injection or intravenous insulin) during admission on ICU
- Admission to ICU within 48hours
Who cannot take part
- Known significant allergy to tape/ adhesives
- Requirement for therapeutic temperature control (i.e. cooling) post cardiac arrest
- Imminent death or anticipated length of stay <24hours
- Women who are pregnant
- Imminent extracorporeal membrane oxygenation (ECMO)
Where in United Kingdom
- Imperial College Healthcare NHS TrustLondon, United KingdomContact: Parizad Avari, MBBS, PhDNot yet recruiting
About the trial
What the trial wants to find out
The aim of this observational study is to assess safety and implementation of continuous glucose monitors within the Intensive Care Unit. The Dexcom G7 is a continuous glucose monitoring system that shows blood glucose values in real-time and includes alarms if the glucose is very low or high.
The 2 groups in the trial
- Adjunctive use of continuous glucose monitoring (Dexcom G7) with telemetry (ViewsEMR/CampViews®)
Treatment: Dexcom G7 and ViewsEMR telemetry
- Usual care + masked Dexcom G7
Use of continuous glucose monitoring (Dexcom G7) without telemetry (ViewsEMR/CampViews®)
Treatment: Dexcom G7
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Implementation of Networked Continuous Glucose Monitoring With Telemetry Within the Intensive Care Unit (ICU-TeleCGM)
- Plain-language title
- Using Continuous Glucose Monitors With Remote Viewing in Intensive CareGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 17 August 2026